Susceptibility‐Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial
MicrobiologyOpen · 2026-06 · 15 (3)
DOI: 10.1002/mbo3.70313 ↗Abstract
ABSTRACT Clarithromycin resistance is a major determinant of treatment failure, and the benefits of susceptibility‐guided therapy in high‐resistance settings remains incompletely understood. To evaluate the clinical effectiveness of the susceptibility‐guided compared with the empirical therapy in treatment‐naïve H. pylori infection in a high resistance setting. In this single‐centre, randomised, superiority trial, 500 treatment‐naïve adults were allocated (1:1) to susceptibility‐guided sequential therapy (SGT) or empirical clarithromycin ‐containing quadruple therapy (ET). Clarithromycin and levofloxacin antimicrobial resistance were determined using PCR. The primary endpoint was first‐line eradication in the intention‐to‐treat (ITT) population. Sensitivity analyses were performed using complete‐case and multiple imputation approaches. Among the 494 analysed participants (244 SGT, 250 ET), resistance to clarithromycin and levofloxacin was 69.3% and 51.6%, respectively. In the ITT analysis, first‐line eradication was achieved in 59.8% of participants in the SGT group and 62.8% in the ET group [absolute risk difference −3.0%; odds ratio (OR) = 0.882, 95% confidence interval (CI, 0.614–1.268), p = 0.499]. Per‐protocol eradication rates were 84.4% and 89.7%, respectively [absolute risk difference −5.3%; OR = 0.620, 95% CI (0.328–1.173), p = 0.139]. Notably, despite a clarithromycin resistance rate approaching 70%, empirical clarithromycin‐containing quadruple therapy achieved a high per‐protocol eradication rate. Sensitivity analyses yielded consistent results. In a high resistance region, PCR‐based susceptibility‐guided sequential therapy did not demonstrate superiority over empirical treatment. However, empirical clarithromycin ‐containing quadruple therapy maintained satisfactory efficacy. Overall, these findings have implications for treatment strategy selection in high‐resistance microbiological settings. Trial Registration: ClinicalTrials. gov Identifier: NCT05549115
EUVIMED